Overview
Patients diagnosed with Hodgkin’s lymphoma receive state-of-the-art care from a team of specialists in this disease. SCCA was formed, in part, to bring promising new treatments to patients faster. For lymphoma patients, this means more treatment options than might be found elsewhere.
While we offer standard therapies, our particular expertise is in providing novel therapies to patients who may benefit from them. Many of our patients receive such therapies through clinical research studies conducted at SCCA and its parent organizations, Fred Hutchinson Cancer Research Center and UW Medicine.
If you are newly diagnosed, our team can offer you options. If you’ve had initial treatment that did not cure your disease, we may have other options for you. And if you require a bone marrow transplant, the Fred Hutchinson Transplant Program at SCCA ranked ranked first in outcomes in a five-year study by the National Marrow Donor Program that measured one-year survival rates of patients at 122 transplant centers nationwide.